Versatope Designs Immunity With Our
Transformational Biotechnology Platform
Our designer extracellular transport vesicles provide cross-strain immunity to infectious disease, including Influenza and targeted RNA therapeutics for cancer.
We have a versatile platform based on molecular engineering of Recombinant Extracellular Transport Vesicles (RET-V's).
The Power of RET-V's
- Display Multiple Viral Variants on a Single Vesicle
- Design More Effective Vaccines
- Deliver therapeutic RNA directly into cancer cells
- Protect Against Emerging Strains
- Confer Long-Term Immunity
- Rapid Synthesis, Scale up and Distribution
- Thermostable
A 3-D View of Versatope's Vaccine Design
Take a voyage inside Versatope's vaccine vesicles and learn how we design multi-strain vaccines using probiotic vesicles and why this gives us a competitive advantage over single strain vaccines.